DIOSynVax customizes vaccine antigen design using a patented method that combines computational biology with in vitro and in vivo validation to identify optimal Vaccine Antigen Payload candidates. This technology enhances global vaccine efficacy against existing and emerging viruses by leveraging insights from virus structure and evolution.
Funding
$7.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional vaccine development faces challenges in achieving broad and long-lasting protection against diverse and evolving viral strains. Existing vaccines may not elicit sufficiently robust immune responses or may be limited in their effectiveness against emerging variants.
Solution
DIOSynVax employs a patented computational biology approach to design optimized vaccine antigens, enhancing global vaccine efficacy against both existing and emerging viruses. The technology leverages insights from virus structure and evolution to identify ideal Vaccine Antigen Payload (VAP) candidates. This method combines in silico design with in vitro and in vivo validation, ensuring the selection of antigens that elicit strong and broadly protective immune responses. The data generated through this process continuously refines and improves the antigen designs.
Target Audience
The primary target audience includes vaccine developers, pharmaceutical companies, and research institutions seeking to improve vaccine efficacy and broaden protection against viral diseases.
Features
- Computational design of vaccine antigens based on viral structure and evolutionary analysis
- Patented method for identifying optimal Vaccine Antigen Payload (VAP) candidates
- In vitro and in vivo validation to confirm antigen immunogenicity and efficacy
- Focus on broad protection against existing and emerging viral strains
- Data-driven approach for continuous improvement of antigen designs